Featured Research

from universities, journals, and other organizations

Non-invasive Test Accurately Identifies Gynecologic Malignancies

Date:
April 23, 2009
Source:
American Roentgen Ray Society
Summary:
Diffusion weighted MR can accurately identify benign from malignant pelvic lymph nodes in patients with gynecologic malignancy, according to a study performed at Massachusetts General Hospital in Boston, Mass. Diffusion weighted imaging is a noninvasive test that uses an MRI sequence sensitized to the motion of water molecules within tissue.

Diffusion weighted MR can accurately identify benign from malignant pelvic lymph nodes in patients with gynecologic malignancy, according to a study performed at Massachusetts General Hospital in Boston, MA. Diffusion weighted imaging is a noninvasive test that uses an MRI sequence sensitized to the motion of water molecules within tissue.

“Conventional imaging with CT or MRI uses the size of a lymph node to determine whether it is malignant. Unfortunately, lymph node assessment by size criteria and morphology is not very accurate in detecting metastasis,” said Michael Chew, MD, lead author of the study. This study included pelvic MRI and DWI results of 40 patients with gynecological malignancy. “Our study suggests that DWI can predict lymph node involvement by a tumor with a sensitivity of 92%, specificity of 85% and accuracy of 87%. It has a negative predictive value of 97%, so when DWI determines that a node is not involved by a tumor, it is almost always correct,” he said.

“The choice of correct treatment for patients with gynecological malignancy is often determined by whether the cancer has spread to the nodes. DWI can help to depict gynecologic malignancy more clearly and provide useful information regarding lymph node metastasis so that patients are directed to the appropriate treatment,” said Dr. Chew.

“It is noninvasive, safe and does not involve radiation exposure or the injection of contrast agents. It is a simple method for defining both primary neoplasm and lymph node spread, helping the oncologist decide between surgery and chemoradiation, or to define the extent of surgery that needs to be performed. It also aids in assessing prognosis,” he said.

“Our results are based on a small series of patients at a single institution. The next step is to carry out larger studies that include more patients and institutions. The long-term goal is to improve the care of cancer patients by developing more accurate imaging,” said Dr. Chew.

This study will be presented at the 2009 ARRS Annual Meeting in Boston, MA, on Tuesday, April 28.


Story Source:

The above story is based on materials provided by American Roentgen Ray Society. Note: Materials may be edited for content and length.


Cite This Page:

American Roentgen Ray Society. "Non-invasive Test Accurately Identifies Gynecologic Malignancies." ScienceDaily. ScienceDaily, 23 April 2009. <www.sciencedaily.com/releases/2009/04/090423132658.htm>.
American Roentgen Ray Society. (2009, April 23). Non-invasive Test Accurately Identifies Gynecologic Malignancies. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/04/090423132658.htm
American Roentgen Ray Society. "Non-invasive Test Accurately Identifies Gynecologic Malignancies." ScienceDaily. www.sciencedaily.com/releases/2009/04/090423132658.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins